Literature DB >> 30165232

Postoperative Intracerebral Hemorrhage After Combined Revascularization Surgery in Moyamoya Disease: Profiles and Clinical Associations.

Kikutaro Tokairin1, Ken Kazumata2, Haruto Uchino2, Masaki Ito2, Kota Ono3, Ryota Tatezawa2, Takafumi Shindo2, Masahito Kawabori2, Naoki Nakayama2, Kiyohiro Houkin2.   

Abstract

OBJECTIVE: In combined revascularization surgery for patients with moyamoya disease, intracerebral hemorrhage (ICH) during the postoperative acute phase is a rarely observed but severe complication. Its clinical features remain unclear because of its low incidence rate. The aim of this study was to clarify the clinical characteristics of immediate postoperative ICH.
METHODS: The frequency, onset timing, and hematoma location of patients who demonstrated immediate postoperative ICH were investigated in 201 consecutive surgeries performed in 134 patients. Associations between immediate postoperative ICH and demographics, clinical presentation type, perioperative blood pressure (BP), and neuroimaging data were analyzed.
RESULTS: Postoperative ICH was observed in 6 cases (2.99%; mean age, 46.0 ± 7.6 years). The onset timing of ICH was within 24 hours after surgery in most patients (83.3%). Hematomas were located at the subcortical lesion beneath the anastomosed cortex (n = 5) and caudate head (n = 1). Three cases (50.0%) required hematoma evacuation. A higher age at surgery was associated with postoperative ICH (P = 0.046). In adult cases (132 surgeries, 65.7%), hemorrhagic presentation at onset (P = 0.0027) and an increase in BP from pre- to postoperative stage (systolic BP increase: P = 0.0058, diastolic BP increase: P = 0.0274) were significantly associated with postoperative ICH.
CONCLUSIONS: The results suggest that older patients, with hemorrhagic presentation and greater postoperative BP increase, should be carefully managed to avoid postoperative ICH. Immediate hematoma evacuation may be effective in preventing devastating outcomes after postoperative ICH.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood pressure; Cerebral hyperperfusion syndrome; Cerebral revascularization; Hematoma evacuation; Intracerebral hemorrhage; Moyamoya disease

Mesh:

Year:  2018        PMID: 30165232     DOI: 10.1016/j.wneu.2018.08.132

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Pre-operative higher hematocrit and lower total protein levels are independent risk factors for cerebral hyperperfusion syndrome after superficial temporal artery-middle cerebral artery anastomosis with pial synangiosis in adult moyamoya disease patients-case-control study.

Authors:  Masahito Katsuki; Miki Fujimura; Ryosuke Tashiro; Yasutake Tomata; Taketo Nishizawa; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2020-09-24       Impact factor: 3.042

2.  Moyamoya Disease-Standards and Advances in Revascularization Procedure and Peri-operative Management.

Authors:  Miki Fujimura
Journal:  Adv Tech Stand Neurosurg       Date:  2022

3.  Measurement of Intraoperative Graft Flow Predicts Radiological Hyperperfusion during Bypass Surgery in Patients with Moyamoya Disease.

Authors:  Akikazu Nakamura; Akitsugu Kawashima; Shunsuke Nomura; Takakazu Kawamata
Journal:  Cerebrovasc Dis Extra       Date:  2020-07-29

4.  Cerebral Hyperperfusion and Concomitant Reversible Lesion at the Splenium after Direct Revascularization Surgery for Adult Moyamoya Disease: Possible Involvement of MERS and Watershed Shift Phenomenon.

Authors:  Ryosuke Tashiro; Miki Fujimura; Taketo Nishizawa; Atsushi Saito; Teiji Tominaga
Journal:  NMC Case Rep J       Date:  2021-08-06

5.  Intraoperative Early Venous Filling Phenomenon as an Intrinsic Sign of the Local Hemodynamic Change after Revascularization Surgery in a Patient with Adult Moyamoya Disease: Implications of a Potential Arteriovenous Shunt.

Authors:  Kikutaro Tokairin; Taku Sugiyama; Masaki Ito; Miki Fujimura
Journal:  NMC Case Rep J       Date:  2021-11-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.